For discussion: The Supreme Court should get more involved in patent cases. Not less!

Reading time: 15 minutes
Question of law, or fact, or what?!

When I first read about questions of law (‘Rechtsfragen‘) and questions of fact (‘Tatfragen‘) in my younger years, I memorized something like this:

    • Questions of fact can be proven, and – as a rule – evidence is required.
    • Questions of law can be answered by applying the law to the facts at hand.

And I felt like «okay, got it; what’s next?» My goodness, how naïve I was. Much smarter people than I have been racking their brains over this for a long time. Meanwhile I feel more like there just is no clear and workable solution for differentiating between the two terms. I have once been told with a smirk that anyone who says otherwise just hasn’t thought about it long enough. There is undoubtedly some truth in that.

Why does the disctinction between questions of law and questions of fact matter?

It matters because the Supreme Court (SC) bases its judgments on the facts established by the lower court (Art. 105(1) SCA). It may correct or supplement the lower court’s findings of fact only if they are obviously incorrect or based on a violation of law within the meaning of Art. 95 SCA (e.g. the PatA); moreover, the correction of the defect must be decisive for the outcome of the proceedings (Art. 97(1) and Art. 105(1) SCA). According to the established case law of the SC, «obviously incorrect» means «arbitrary». The bottom line at least in my experience in patent matters is that the hurdle to get facts corrected on appeal is … anything but a hurdle; it’s effectively a wall.

But there is still a glimmer of hope in any appeal: The legal issues!

Malicious gossip has it that it is always a question of law when the SC wants to decide it. Otherwise, it is not. I cannot know.
The skilled person, a FREAKY species

The most controversial issues in patent litigation are to be decided from the viewpoint of the skilled person. Novelty, (non-)obviousness, sufficiency of disclosure, allowability of amendments, … it all hinges on how the skilled person understands and approaches the matter. To complicate things even further: The skilled person is a legal fiction (Bernard CORBOZ in OJ EPO 2009, Special ed. 1). And what a weird guy he is! With reference to Lord REID in 1972 R.P.C. 346, Sir Robin JACOB put it like this:

It is settled that this man, if real, would be very boring — a nerd.

Oh, and he is also very forgetful, as JACOB rightly pointed out:

Beware of nerds

So, in a nutshell, some of the most controversial – and interesting – issues in patent litigation are to be decided from the viewpoint of a fictionary person, a somewhat skilled but very forgetful nerd (oh, or maybe even an assembly of nerds).

There is good and bad about this. Thinking about appeals to the SC:

✅ Good is that whatever that legal fiction of a skilled person understands or does cannot be a question of fact; what a legal fiction thinks or does is a question of law. As the German Supreme Court put it in X ZR 255/01 — Bodenseitige Vereinzelungsvorrichtung:

Accordingly, the SC should have a look at it.

❌ There will hardly ever be a universal truth: The skilled nerd simply cannot be asked. Accordingly, it can hardly ever be said that a first instance assessment is objectively wrong. We need to live with what comes closest to what is right. What is more, most patent cases are technologically quite demanding, and the FPC has judges with a technical training on the bench. Unlike the Supreme Court. All this might well result in quite some hesitation to intervene. The first instance assessment may easily amount to an anchoring fact, resulting in an anchoring bias in one’s own re-assessment. That would be bad (very bad).

Now, what are the chances of an appeal?

When filing an appeal in patent matters in Switzerland, one should not be overly enthusiastic about it. Chances are close to zero. By way of example, let’s have a look at the last calendar year (snapshot from the FPC’s annual report for 2021):

Statistics with small numbers are always a struggle. But 2021 was not an exception. In 2020, the SC dealt with 11 cases in patent matters: Eight appeals were dismissed, one was shelved, yet another one remitted to the FPC for further consideration / to complete the facts (the case was about the recusal of a judge for the appearance of bias; the skilled nerd couldn’t care less) — and only a single appeal was allowed. The latter undoubtedly pertained to a question of law, i.e. (im)proper novae (not an issue for the skilled nerd either).

So, just looking at the last 2.5 years: Not a single appeal has been allowed on the FPC’s assessment of how a skilled nerd approached the matter. Looking further back in time does not change much in this respect. From the top of my head, I do not recall a single appeal where the SC overruled the FPC’s assessment of what the skilled nerd had (not) understood from a piece of prior art or had (not) been prompted by the prior art to do in the expectation of some advance.

Yes, I know, there was ‘Fulvestrant’. But I feel that 4A_541/2017 does not count because the SC only corrected how the ‘objective technical problem’ was to be phrased when starting from an insufficiently disclosed closest prior art document. Interesting. But how the ‘objective technical problem’ is to be phrased is not sth the skilled nerd is concerned with. It’s a technicality of the problem-solution approach. What I am looking for is an intervention e.g. at the «could/would-approach» stage. But I could not find any.

As always, I stand to be proven wrong, but it appears that the SC never had any issues with the FPC’s assessment of what the skilled nerd would (not) have understood or done. Whenever the FPC ruled on such an issue, i.e. when it stepped into the shoes of the skilled nerd, the SC never intervened.

Now, what does that tell us?

Always right …?

I would love to think that the FPC hands down perfectly right judgments in each and every case, to the extent the actual assessment of a case on the merits from the viewpoint of the skilled nerd is concerned.

But, frankly: How realistic is that?

If you have ever attended a high stake hearing with attorneys seriously arguing a borderline case on obviousness, you will appreciate that there can hardly ever be a universally correct b/w decision. (And most cases at the FPC are borderline cases; that’s why reasonable parties need to involve the court.) Putting oneself in the shoes of the skilled nerd and to decide on what he would (not) have understood or done back in the days is anything but easy, and the outcome is almost never non-controversial. Accordingly, shouldn’t it raise an eyebrow when first instance decisions on the nerdish issues of novelty, obviousness, sufficiency of disclosure and allowability of amendments are practically never lifted?

Meanwhile, in Germany …

According to  the most recent Busse/Keukenschrijver (9th ed. 2020; §110, no. 18), about 50% of all nullity decisions of the Federal Patent Court in Germany are lifted by the Supreme Court (BGH):

total # conf’d # lifted #
2017 33 16 (48%) 17 (52%)
2018 41 22 (54%) 19 (46%)

At closer scrutiny, the BGH mostly amends the FPC’s decision in the patentee’s favour (which fits well with the FPC’s reputation as the ‘graveyard of patents’). Still, some decisions are also amended in the plaintiff’s favour:

lifted # pro pat. # pro plt. #
2017 17 14 (82%) 3 (18%)
2018 19 18 (95%) 1 (5%)

[pro pat., decision amended pro patentee; pro plt., decision amended pro plaintiff]

The FPC apparently errs in a substantial number of cases. At least the FPC in Germany does. And the BGH does not shy away from correcting the assessment on the merits of a case. Notably, in my understanding, the legal framework is essentially the same as in Switzerland (cf. §110 and §111 DE-PatA).

… and at the EPO

The ODs of the EPO have a huge experience in re-assessing novelty, obviousness, sufficiency of disclosure and allowability of amendments of granted patents. Thousands of European patents are opposed each and every year (e.g., 3’247 patents were newly opposed in 2020, and 1’912 opposition cases were decided in 2020 by the ODs in first instance).

With such a wealth of experience (over decades!), there should hardly be any wrong decisions anymore. One would think so. But far from it. The BoA constantly sort out about 60% of all first instance decisions, each and every year:

Don’t get me wrong, this is not because the ODs do a bad job. Actually, they do a fantastic job to very large extent, in my experience. It is simply because people make mistakes — despite their vast experience. We all do.

I conclude from all this that one might reasonably assume that a typical first instance decision assessing validity of a patent from the point of view of a skilled nerd in inter partes proceedings should be lifted with quite a high likelihood when a second instance really re-assesses the case. Not so in Switzerland. The FPC has a perfectly clean record.

I had been chewing on this issue for quite a while when I came across a recent comment in the NZZ that approached the matter from a different perspective.

But let’s first have a closer look at the SC.

Ever more federal judges?

The SC has been struggling with its heavy workload for years. In 2021, the number of pending cases increased even further (3’235 at the end of last year).

In parallel, the overall chances to succeed (in full or in part) with an appeal in civil matters fell to the lowest rate (ever?) over the last ten years in 2021, i.e. 9.8%.

I cannot know whether this trend is just coinciding with the ever increasing workload at the SC, or whether there is a causal link. But, in any event, it is a remarkable — and worrying — trend on its own.

To fight the backlog, the SC inter alia requested that two further judges were appointed, to increase the total number of judges from 38 to 40; see e.g. the latest annual report of the Supreme Court.

In a recent guest comment in the Neue Zürcher Zeitung (NZZ), Ulrich MEYER (the former President of the SC; meanwhile retired) came up with a totally different proposal: The SC should be given more leeway to accept appeals in the first place, or to dismiss them without giving reasons. By far the most appeals did not pertain to questions of law anyway. Rather, arbitrariness is asserted: As MEYER put it, mostly questions of fact in disguise are concerned; the «easiest trick of attorneys.» (That sounds a bit like cheating, doesn’t it?)

However, the Supreme Court has to assess assertions of arbitrariness — and to at least give summary reasons for dismissing such appeals. Too much of a burden!

MEYER suggests to dispense therewith, and to actually reduce the number of judges to only 20. That would be enough staff to get the really important(?) things done. Two follow-up comments have been published in the NZZ: Arnold MARTI dissented and Karl SPÜHLER largely consented with MEYER.

What kind of Supreme Court should we want?

MEYER’s proposal rang alarm bells with me; see my first thoughts on LinkedIn. I am convinced that it would be a disaster in patent cases. The FPC is the first instance in patent infringement and validity litigation, and appeals go directly to the SC:

If the SC would not even give its summary reasons anymore when it dismisses an appeal, the whole appeal stage will likely be perceived as a mere rubber-stamping exercise. I would not want it that way.

Btw, MEYER is right in this respect: We mostly do see only very brief summary reasons. It sometimes feels like a resounding slap in the face of the appellant: How could you even bring this argument?! It could go like this:

However, appellant is not able to show a violation of Art. … [123 / 54 / 56 EPC, you name it] by merely contrasting the understanding of the lower court, according to which … [citing a bit from the judgment under appeal], with its contrary view. The lower court is not to be accused of a violation of law when it … [yet another bit from the judgment under appeal]; rather, the lower court comprehensibly pointed out … [and yet another bit from the judgment under appeal]. The appellant merely criticizes this reasoning in a sweeping manner as arbitrary; appellant is also unable to substantiate in more detail to what extent … [citing a bit from the appeal brief].

I frequently fail to spot much of a critical re-assessment in such a line of citations. It comes along as summary reasons, but effectively it’s sometimes not even that. Still, both practitioners and the lower court have something to consider, to learn, or to just struggle with. Summary reasons is not much, but it is something.

But, sometimes, I have radical thoughts:

Wouldn’t it be fantastic if the SC would really (and eagerly!) dive into the nitty gritty details of the most demanding technical issues and openly re-assess them from the viewpoint of the skilled nerd?

What if the Supreme Court would not leave practitioners with the impression that it presumed just another factual critcism in disguise (as MEYER put it) but would rather jump on the subject-matter under appeal to get close(r) to what is right?

In any event, wouldn’t it be great to read more than just summary reasons, maybe even reasons that set precedents for other cases to come? It really is not that all is settled about what the skilled nerd would have understood or done in a given situation. Far from it. On the contrary, I truly feel there is even room for brave landmark judgments in this respect that would be cited elsewhere. Just like Supreme Court judgments from the U.K. or Germany. Judgments are not cited elsewhere because they are right (or wrong); they are cited because they are convincingly – if not even brilliantly – reasoned and thereby set a precedent. I sometimes read high stake UK judgments on a Sunday afternoon, just because they are outstanding reads, with a well elaborated reasoning that sheds light on all facet of the arguments so that the interested reader cannot but concur in the end: Amen, that’s right, indeed. BGH judgments from Germany are of a different kind: Rarely entertaining, but with a razor-sharp analysis of the key issues.

What if we even had a specialized IP chamber at the Supreme Court? This would be nothing out of the ordinary: The BGH meanwhile has two IP chambers (the X. civil chamber exclusively hears patent cases; the I. civil chamber deals with copyright and other IP). In view of the lower case numbers in Switzerland, a combined chamber might make sense for Switzerland.

It ain’t gonna happen, you think?

Well, maybe you’re right. But I see it differently: Switzerland has been named the most innovative country in the world in WIPO’s Global Innovation Index 2021 — the eleventh(!) time in a row. Intellectual property, and patents in particular, cannot be underestimated in this respect: The detailed scorecard shows that Switzerland leads the pack in terms of patents and knowledge creation. I truly feel a specialised IP chamber at the Supreme Court that positions itself as a trailblazer in IP matters would make perfectly sense to reflect this position.

UPDATE 1 September 2022: I have just been pointed to a very interesting article about how the jurisprudence of the Supreme Court evolved over time. I was only scratching the surface. Mark Schweizer compiled a lot more data and insight here: Vom Umgang des Bundesgerichts mit steigender Geschäftslast
– lieber schnell als sorgfältig?, in: «Justice – Justiz – Giustizia» 2016/2.

/MW

Ulrich MEYER, guest comment in NZZ of 20 July 2022:

Arnold MARTI, guest comment in NZZ of 8 August 2022:

Karl SPÜHLER, guest comment in NZZ of 11 August 2022:

BE ON THE KNOW

Enter your name and email address below to get notified of new posts by email.

Generic Kivexa®: Supreme Court confirms interim injunctive relief

Reading time: 7 minutes

Case No. 4A_575/2018 (Supreme Court) | Decision of 12 March 2019 on appeal against S2018_004 (FPC) | Decision of 22 October 2018 | ‘Abacavir / Lamivudine’

Please see this Blog here for a detailed review of the first instance decision S2018_004 of the FPC in this matter, granting interim injunctive relief against Sandoz’s generic Kivexa®.

An appeal against a decision in summary proceedings is not so easy anymore as it used to be. In former times, a not easily repairable harm had routinely be assumed on appeal against decisions concerning interim injunctive relief (see BGE 134 I 83, ¶3.1, with further reference). However, the more recent case law requires that the appellant is threatened by a not easily repairable harm (in legal terms) in the specific case at hand; see BGE 144 III 475, ¶1.2, with further reference). In the case at hand, the Supreme Court left it undecided whether the loss of the first mover advantage or reputational damages would be sufficient to meet the threshold. But the Supreme Court noted that the interim injunctive relief also prohibited possession and storage, and the defendant would thus have to destroy all products on stock. The Supreme Court held that this constitutes a not easily repairable harm in the sense of Art. 93(1) lit. a SCA, and the appeal was admissible already for this reason. This surely is lawyer’s playground; but I am wondering why the loss of stock was considered a not easily repairable harm? It surely is a harm. But wouldn’t it be one of the kind that is quite easy to repair?

Further, Sandoz had argued that the plaintiff was not actually at risk of a ‘not easily repairable harm’ as required by Art. 261(1) lit. b CPC.

ViiV corporate tree (section), as illustrated by respondent

In brief, plaintiff ViiV Healthcare UK Ltd is the holder of the Swiss SPC, and is fully owned by ViiV Healthcare Ltd; cf the right branch of the illustration. Likewise, ViiV Healthcare GmbH (holder of the Swiss MA for Kivexa® according to the ‘Spezialitätenliste‘) is fully owned by ViiV Healthcare Overseas Ltd, which in turn is fully owned by ViiV Healthcare Ltd; cf the left branch of the illustration.

The FPC had held that a not easily repairable harm was sufficiently credible; it was ‘obvious and notorious’ that in such group structures of pharmaceutical companies a disadvantage that cannot be easily repaired arises for the group and thus at least indirectly also for the formal holder of the SPC. The FPC failed to see why / to what extent this should not be the case in the present setup.

Es ist offensichtlich und notorisch, dass in derartigen Gruppenkonstellationen von pharmazeutischen Konzernen ein nicht leicht wiedergutzumachender Nachteil bei der Gruppe anfällt und damit wenigstens indirekt auch bei der formellen Inhaberin des Schutzrechts. Inwiefern dies in der vorliegenden Konstellation nicht der Fall sein sollte, ist nicht ersichtlich.

The Supreme Court essentially confirmed this reasoning.

The decision also discusses the dispatch of the Federal Council on the Civil Procedure Code and holds that any impairment of the execution of absolute rights constitutes a not easily repairable harm; BBl 2006, ¶5.19, p. 7354:

[…], wird in der Botschaft zur ZPO ausgeführt, jede Beeinträchtigung in der Ausübung absoluter Rechte bedeute einen nicht leicht wieder gutzumachenden Nachteil ([…]).

Frankly, I don’t see that in the dispatch. In my reading, the dispatch only holds that any impairment of the execution of absolute rights constitutes a harm, but it does not say that this harm is automatically not easily repairable:

Als Nachteil gilt beispielsweise eine Beeinträchtigung der Ausübung absoluter Rechte (z.B. Störung des Eigentums).

As to the alleged lack of novelty over D1 (WO 96/06844), the Supreme Court held that the FPC did not arbitrarily acknowledge novelty based on multiple selections from lists.  In my perception, the Supreme Court suggests that the standard established by the case law of the Boards of Appeal of the EPO in relation to selections from multiple lists of certain length shall be applicable:

Die Beschwerdeführerin stellt zu Recht nicht in Frage, dass auf die Praxis der Beschwerdekammern des EPA abgestellt werden kann.

Thus, let’s do it. Here is the critical paragraph of D1:

[Abacavir] may be administered alone or in combination with […] Nucleoside Reverse Transcriptase Inhibitors (NRTIs) for example zidovudine, zalcitabine, lamivudine, didanosine, stavudine, 5-chloro-2′,3′-dideoxy-3′-fluorouridine and (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; non-NRTIs for example nevirapine and α-APA; HIV protease inhibitors for example saquinavir; other anti-HIV agents for example soluble CD4; immune modulators for example interleukin II, erythyropoetin, tucaresol; and interferons for example a-interferon.

Now, does it require a multiple selection from two lists of certain lengths to arrive at the combination of abacavir and lamivudine, in accordance with the established case-law of the Boards of Appeal of the EPO? Does one have to first choose a generic class (NRTIs) and then lamivudine within that class — or does one just have to pick one compound from a single (structured) list of compounds? A decision on that question could have been a very interesting read. But the Supreme Court merely held that the FPC could well assume, without becoming arbitrary, that it would still require a twofold choice and thus a multiple selection from D1.

Selbst wenn daher die Rüge der Beschwerdeführerin begründet wäre (was offen bleiben kann), dass die im angefochtenen Entscheid genannte erste Auswahl keine relevante Wahl im Sinne der Rechtsprechung sein sollte [Anm.: Mono- bzw. Kombinationstherapie], konnte die Vorinstanz ohne in Willkür zu verfallen davon ausgehen, es erfordere immer noch eine zweifache Wahl und damit eine Mehrfachauswahl aus [D1], um zum Gegenstand des Patents der Beschwerdegegnerin zu gelangen.

Now, what? Does any ‘twofold selection’ whatsoever create novelty? I don’t think so. What about the requirement of the Boards of Appeal that the lists have a ‘certain length’? And what about the argument that the above is only a single, yet structured list? While the FPC clearly intended to follow the EPO’s approach, I am not so sure about the Supreme Court’s view on this. Anyway, time will tell …

Reported by Martin WILMING

BIBLIOGRAPHY

Case No. 4A_575/2018 (Supreme Court) | Decision of 12 March 2019 on appeal against S2018_004 (FPC) | Decision of 22 October 2018 | ‘Abacavir / Lamivudine’

ViiV Healthcare UK Ltd. (respondent / plaintiff)
./.
Sandoz Pharmaceuticals AG (appellant / defendant)

Panel of Judges:

  • Dr. Christina KISS
    • Dr. Kathrin KLETT
    • Dr. Martha NIQUILLE

Court Clerk:

  • Linus HUG

Representative(s) of ViiV:

  • Dr. Simon HOLZER (MLL)
  • Louisa Galbraith (MLL)

Representative(s) of Sandoz:

SUPREME COURT
on appeal against S2018_004 (FPC) | Decision of 22 October 2018
Case no.: 4A_575/2018
Decision of: 12 March 2019
Fullscreen view (new tab)

PATENT COURT
Case no.: S2018_004
Decision of: 22 October 2018
Fullscreen view (new tab)

PATENT IN SUIT

Fullscreen view (new tab)

BE ON THE KNOW

Enter your name and email address below to get notified of new posts by email.

Riendeau ./. Zehnder: Heat exchanged?

Case No. 4A_277/2018 ¦ Decision of 01 October 2018 (Supreme Court) on appeal against O2015_009 ¦ Decision of 21 March 2018 ¦ ‘Wärmeaustauschelement: Feststellung der gemeinsamen Berechtigung an der Anmeldung’

Note that Hepp Wenger Ryffel is involved in this matter on behalf of the plaintiff / appellant.

Please see this Blog here for a discussion of the underlying decision of the FPCIn brief, it is all about an assignment action of Marcel Riendeau against Zehnder Group International AG, concerning two European patent applications, i.e.:

Both EP2 and EP3 had been filed in Zehnder’s name only; the plaintiff had been designated as inventor. The plaintiff had partially suceeded in first instance when the FPC held that the parties are jointly entitled to both patent applications.

On appeal, the plaintiff objected that the facts had been wrongly established in the first instance decision in various aspects, that the burden of proof had been incorrectly allocated and that the FPC had not dealt with the plaintiff’s entitlement to a transfer of the patent applications based on a contractual undertaking.

To cut a long(er) story short: The Supreme Court did not agree and dismissed the appeal. The FPC’s decision is thus final now, and it remains to be seen how the parties get along with their joint entitlement to both EP2 and EP3.

Reported by Martin WILMING

BIBLIOGRAPHY

Case No. O2015_009 ¦ Decision of 21 March 2018 ¦ ‘Wärmeaustauschelement: Feststellung der gemeinsamen Berechtigung an der Anmeldung’

Marcel Riendeau
./.
Zehnder Group International AG

Panel of Judges:

  • Dr. Christina KISS
    • Dr. Kathrin KLETT
    • Marie-Chantal MAY CANELLAS

Court Clerk:

  •  Nicolas CURCHOD

Representative(s) of Plaintiff:

Representative(s) of Defendant:

SUPREME COURT DECISION

Fullscreen view (new tab)

FPC DECISION

Fullscreen view (new tab)

EP 2 829 834 A1
(referred to as EP2 in the decisions)

Fullscreen view (new tab)

EP 2 829 836 A1
(referred to as EP3 in the decisions)

Fullscreen view (new tab)

BE ON THE KNOW

Enter your name and email address below to get notified of new posts by email.

Supreme Court confirms FPC’s decision O2015_008 — Omega’s appeal dismissed

Case No. 4A_282/2018 ¦ Decision of 4 October 2018 (Supreme Court) on appeal against O2015_008 ¦ Decision of 14 March 2018 (FPC)¦ ‘Balancier de montre’

Reading time: 5 minutes

As to the background of this matter, please see the report about the main hearing on this Blog here and the discussion of the first instance decision of the FPC on this Blog here.

In brief, Omega had alleged infringement of its EP 1 837 719 B1; see the EPO Register and Swissreg for further bibliographic details of the patent in suit. With decision of 14 March 2018, the FPC had rejected Omega’s claim for infringement while Tudor’s / Detech’s counterclaim for invalidity had been allowed; EP(CH) 1 837 719 B1 had been declared invalid.

The Supreme Court now dismissed Omega’s appeal, i.e. confirmed the FPC’s decision. EP(CH) 1 837 719 B1 is thus finally declared invalid.

The issues dealt with by the Supreme Court in the decision, in brief:

  1. Age of a prior art document 

On appeal, Omega has argued that the FPC took an unrealistic piece of prior art into account in the assessment of inventive step. Indeed, the FPC had considered a document that was published already about a century ago, i.e. US 759,914. In view of the evolution of watchmaking since then, Omega considered it unrealistic that such a document was actually considered as a starting point in the assessment of inventive step. Consequently, Omega alleged a violation of Art. 56 EPC.

The Supreme Court did not buy this argument. It is held in no uncertain terms that everything that had been made publicly available — including old documents — forms part of the prior art. One cannot exclude a document from consideration in the assessment of inventive step just because of its age; see ¶3.1.3.

Écarter un document de ceux que consulterait l’homme de métier en raison de son ancienneté reviendrait à priver les brevets ayant dépasé un certain âge de toute valeur dans le cadre de l’analyse de l’effet invenif. Un telle pratique ne saurait être déduite de l’art. 65 CBE.

Reference to some case-law of the Boards of Appeal of the EPO did not help either: The mere age of a document has not been decisive in T 479/00, T 366/89, T 1000/92 and T 334/92. The Supreme Court notes that the obsolescence or outdatedness of a technology had been the key issue in these decisions, which excluded the respective documents from consideration by the skilled person. Apparently, no such case had been established by the appellant in the present matter.

  1. Incompatibility of technical teachings

The balance wheel of US 759,914 has inertia blocks that must have been placed from the inside, as claimed by the patent in suit; see the screw head on the inner side of the felloe in the figures below.

But what is still missing here is the stud (‘plot’) according according to the patent in suit. Omega argued that the skilled person would not have added studs to the balance of US 759,914 in view of the risk to impair the automatic adjustment of its temperature dependent moment of inertia, which is the sole purpose of this invention. However, the Supreme Court holds that this is not in agreement with the fact findings of the FPC, and thus did not consider this argument any further.

  1. Choice of the closest prior art

The FPC had not explicitly motivated its choice of US 759,914 as the closest prior art in the assessment of inventive step in accordance with the problem-and-solution approach.

Kind reminder …

And the Supreme Court indeed acknowledges that it would have been desirable if it had done so.

Ainsi, il eût été souhaitable que la juridiction précédente détaille la première étape de l’approche problème-solution comme elle l’a fait pour les autres étapes de son examen.

But still, in view of the FPC’s detailed discussion of how the skilled person had arrived at the invention starting from US 759,914 without inventive merit, it became sufficiently clear how close both inventions actually are, and why US’914 thus is a reasonably chosen closest prior art.

  1. Late filed auxiliary requests / claim limitations

Omega had filed yet another, even more limited auxiliary request (AR3) with the response to the expert opinion of the judge-rapporteur. The FPC had not admitted this request into the proceedings anymore, with reference to O2015_012.

Omega had challenged this on appeal. But while this appeal has been pending, the Supreme Court ruled on the appeal against O2015_012 — and backed the practice of the FPC in this respect; decision 4A_543/2017 of 08 May 2018, see this Blog here. Accordingly, Omega did not succeed with this argument, either.

In sum, Omega’s appeal was dismissed and EP(CH) 1 837 719 B1 is now finally declared invalid.

Reported by Martin WILMING

BIBLIOGRAPHY

Case No. 4A_282/2018 ¦ Decision of 4 October 2018 (Supreme Court) on appeal against O2015_008 ¦ Decision of 14 March 2018 (FPC) ¦ ‘Balancier de montre’

Omega S.A.

./.

  1. Montres Tudor S.A.
  2. Detech S.A.

Panel of Judges:

  • Dr. Christina KISS
    • Dr. Kathrin KLETT
    • Marie-Chantal MAY CANELLAS

Court Clerk:

  •  Nicolas CURCHOD

Representative(s) of appellant / plaintiff:

Representative(s) of defendants / respondents:

SUPREME COURT DECISION 

Fullscreen view (new tab)

FPC DECISION 

Fullscreen view (new tab)

PATENT IN SUIT

Fullscreen view (new tab)

BE ON THE KNOW

Enter your name and email address below to get notified of new posts by email.